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Chronic obstructive pulmonary disease (COPD) is an increasing health problem and one of
the leading causes of morbidity and mortality worldwide, but knowledge about its
pathogenesis has increased substantially in recent years. The disease results from
interaction between individual risk factors (like enzymatic deficiencies) and environmental
exposures to noxious agents, like cigarette smoking, occupational dusts, air pollution and
infections in childhood. The main mechanisms that may contribute to airflow limitation in
COPD are fixed narrowing of small airways, emphysema and luminal obstruction with
mucus secretions. COPD is characterised by a chronic inflammatory process in the
pulmonary tissue, with a pattern different from bronchial asthma, associated with
extrapulmonary effects and is considered now a complex, systemic disease. Optimal
therapeutic targeting of COPD depends on a clear understanding of the precise
mechanisms of these complex processes and on early and correct evaluation of disease
severity. A combination of pharmacological and non-pharmacological approaches is used to
treat COPD. Bronchodilators are the mainstay of COPD treatment and can be combined
with inhaled corticosteroids for greater efficacy and fewer side effects. The use of LTOT for
hypoxemic patients has resulted in increased survival, and expanded drug therapy options
have effectively improved dyspnoea and quality of life. Recent studies have documented
the benefits of pulmonary rehabilitation. In addition, non-invasive mechanical ventilation
offers new alternatives for patients with acute or chronic failure.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
roma2.it (M. Cazzola).Epidemiology and risk factors of chronic
obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a relatively
new term for an old disease. Terms such as ‘‘bronchitis’’,
‘‘emphysema’’, ‘‘asthmatic bronchitis’’ and ‘‘chronic bron-
chitis’’ were more commonly used in the past to describe
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important papers published on the topic over the last 100
years in Respiratory Medicine and its previous versions
British Journal of Tuberculosis, British Journal of Tubercu-
losis and Diseases of Chest and British Journal of Diseases of
Chest.
Several publications have addressed the risk factors of
COPD in the general population although early ones included
only cohorts of working men with limited income.1,2
Rimington1 analysed data from mass radiography units and
concluded that patients with chronic bronchitis were more
likely to be old, heavy smokers and belong to a low social
class. The mean age-adjusted prevalence rate for chronic
bronchitis in that cohort was 12.3% in all men and 5.6% in all
women. However, this was highest in patients who smoked
20 or more cigarettes per day (20% and 18.5% in men and
women, respectively). In a subsequent publication, the
same author demonstrated that the prevalence of chronic
bronchitis in individuals who inhaled while smoking was 50%
higher than in those who did not.2 It is unclear why only a
minority of smokers develop a clinically significant disease.
In addition to smoking, genetic risk factors such as alpha1-
antitrypsin deficiency play an important role in some
patients.3–5The impact of COPD
COPD is associated with significant morbidity and mortality
worldwide and is currently a global health priority. In 1954,
a study by Stuart-Harris6 evaluated the epidemiology and
evolution of chronic bronchitis and described morbidity data
collected from practitioners’ visits, industrial records and
National Insurance data. These data revealed that in 1950,
‘‘bronchitis’’ was the second leading cause of incapacity
from sickness and the sixth most common cause of claims of
sickness in both men and women in Great Britain. Bronchitis,
as a cause of sickness, was scattered over the whole ages in
women but was more common in old men than young men.
However, the author admits that there was no way to
differentiate acute bronchitis from chronic bronchitis from
that database. The same paper evaluated another field
survey of patients with bronchitis and described a group of
symptomatic patients with a ‘‘triple complex’’ syndrome of
cough, sputum and disability (dyspnea or history of exacer-
bation). Patients with this ‘‘triple complex’’ were more
likely to be old and had a high incidence of hospitalization.
This was one of the few papers published at that time which
attempted to classify the severity of COPD. In a subsequent
paper published in 1964, the formation of a bronchitis
registry in East London was described and patients were
divided into three groups (Group 0, 1 and 2) according to
severity of symptoms and lung function abnormality.7 The
authors further analysed the characteristics and the impact
of the disease in these groups demonstrating that patients
belonging to Group 2 had the highest morbidity and had
more time lost from work than patients in the other two
groups.7 The burden of COPD in different countries was a
focus of several publications over the last 100 years.8–13 In a
report published in 1960 from the East London cohort,
Caplin and Silver8 reported that unemployment and time
lost from work were significant in patients with chronicbronchitis. The authors concluded that ‘‘the chronic
bronchitic suffers from two disabilities which may make it
difficult for him to retain his usual employment or find a new
employment. These are increasing shortness of breath on
exertion and lung infections which force him to be away
from worky’’. It is of great interest that almost 50 years
later, the same problems are major causes of disability in
patients with COPD. Utilization of healthcare services and
hospitalizations driven by disease severity account for a
major component of the total cost of COPD worldwide.13–20
The confronting COPD in North America and Europe survey
which was the first large-scale international survey of the
burden of COPD estimated the annual cost of healthcare
utilization in the US at $4119 per patient with COPD, with
indirect cost of $1527 per patient. The annual estimated
societal cost was $5646 per patient. Inpatient hospitaliza-
tion accounted for the majority of this cost ($2891).9 The
same survey revealed that patients with COPD often
underestimate the severity of their illness. Exacerbations
of COPD account for 35–45% of the total per capita health-
care costs for COPD; however, these costs vary considerably
with the severity of the exacerbation as well as the severity
of COPD.20COPD in special populations
Although COPD has for a long time been considered a disease
of old Caucasian men, recent data from the US show that
mortality is rising faster among women and African-Amer-
icans.21 In a recently published study describing the
characteristics of patients with COPD from a research
database, Caucasians had less loss of lung function per
pack-year smoked than African–Americans which was also
less in men than women suggesting that indeed African–A-
merican women are most susceptible to the ill effects of
smoke compared to other groups of men and women.22
Findings from the Confronting COPD International Survey,
also indicate that gender differences in COPD care and
outcomes do exist and need to be further explored.23
Women with COPD were less likely to have had spirometry
testing, but more likely to have received smoking cessation
advice. Furthermore, women were more likely to report
severe dyspnoea, had similar cough but less sputum
production than men.
While any patient above the age of 40 is at risk of
this disease, patients with advanced age are at higher risk
of complications and increased morbidity from this dis-
ease.24 A report from the obstructive lung disease in
northern Sweden studies demonstrated that almost 50% of
elderly smokers fulfilled the criteria for COPD according to
both the BTS and GOLD guidelines.25 However, while
guidelines recommend the use of a post-bronchodilator
ratio of forced expiratory volume in 1 s (FEV1)/FVCo70% to
define COPD, the physiologic cutoffs for the defining COPD in
elderly patients is still unknown. Furthermore, COPD in
the elderly is associated with impaired health status
which may not necessary be predicted by lung function
tests.26,27 Important determinants of health status in this
population include activity of daily living (ADL) and
emotional status.27
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The clinical presentation of patients with COPD is far from
uniform. This fact has been very well described in several
classic publications in the British Journal of Diseases of the
Chest.28–30 Most patients with COPD present in the fifth or
sixth decade of life although patients with alpha1-anti-
trypsin deficiency may present at a younger age.4,5
Furthermore, symptoms of COPD vary among patients.
While most patients with COPD present with symptoms of
cough and shortness of breath on exertion, many others
have minimal symptoms early in their disease process.
Several screening questionnaires have been developed for
use in everyday clinical practice to facilitate the diagnosis of
COPD in a primary care setting.31–33
A complete assessment of a COPD patient should include
physiologic measures of lung function. Spirometry is the
most widely used and feasible test which can be performed
in the primary care setting.34 The diagnosis of COPD is made
if the post-bronchodilator FEV1/FVC ratio is o70% although
the FEV1/FEV6 ratio may be used as an alternative as it has
been shown to correlate with FEV1/FVC.
35 Evaluation of
acute bronchodilator response should not be used alone as
an index to differentiate asthma from COPD as many
patients with COPD demonstrate significant reversibility to
acute bronchodilator administration.36 Other tests of lung
function such as measurement of lung volumes (e.g.;
inspiratory capacity at rest and during exercise) can shed
more details on the physiologic abnormalities present in
COPD although such tests are rarely needed on routine
assessment.37,38 Exercise intolerance in patients with COPD
can be assessed either by measuring the walking distance
(e.g., six minute walk test) or by performing formal exercise
testing using treadmill or cycle ergometry.39–41
Diagnosis of COPD in the community is more likely in
patients with worse lung function and health status and in
patients who are symptomatic.42 However, attaining a
correct and early diagnosis in the primary care setting
remains challenged by the delay and infrequent use of
spirometry in that setting due to lack of adequate training in
its use and interpretation.43 This is compounded by the lack
of knowledge about COPD by patients at risk such as heavy
smokers.44 Furthermore there is no clear correlation
between symptoms, effort intolerance, and objective
measures of lung function.45,46 This has been clearly
described in a classic article published in the British Journal
of Diseases of the Chest in 1961 which studied a group of in-
patients with chronic obstructive airway disease attending
the London Chest Hospital.45 Despite being a pilot study, this
manuscript sets out to grade the severity of disease and
assess the clinical value of using various tests in patients
with ‘‘chronic obstructive airway diseases’’. The authors
studied effort intolerance, lung function, arterial blood gas
analysis and exercise desaturation and suggest that asses-
sing severity of the disease should include more than one
measure. It is of interest that 60 years later, grading the
severity of COPD continues to be an important clinical
dilemma. While current guidelines suggest using the percent
predicted FEV1 to assess severity of the disease, recent
studies suggest that the use of multidimensional grading
systems may be more useful in assessing the severity and
impact of COPD.47 Furthermore, the use of radiologicalstudies to evaluate the lung parenchyma and airway wall
thickness may aid in differentiating between the different
COPD severity phenotypes.48,49
Management guidelines for COPD
Several guidelines for the management of COPD have been
published.50–56 While the main goals for these guidelines are
to achieve better standards for the diagnosis, treatment and
prevention of COPD, unfortunately these guidelines have not
been widely implemented.55–57 Furthermore, primary care
physicians who treat the majority of patients with COPD
often find the guidelines complicated and thus show a major
gap in the knowledge of all core elements of these
guidelines.57 A major problem with existing guidelines is
that they are usually based on efficacy and not on
effectiveness studies, and do not properly focus the process
of behavioural changes of health professionals and pa-
tients.56 Furthermore, as rapid changes may occur in the
treatment of COPD, future guidelines should be able to
adapt to these rapid adjustments.
Prognostic factors and health outcomes in
COPD
COPD has a progressive course especially in patients who
continue to smoke. Several studies have addressed risk
factors associated with progression of COPD.58–60 Early
studies performed on case series of patients with COPD,
demonstrate that the severity of airflow obstruction,
hypoxaemia, hypercapnia and dyspnoea, and the presence
of co-morbidities such as congestive heart failure are
important indicators of poor prognosis in COPD.59,60 A more
recent paper described important gender differences in the
predictors of decline of lung function in mild to moderate
COPD.58
Although lung function remains the most important
objective outcome in assessing the severity and prognosis
of patients with COPD, success of treatments for this disease
is usually evaluated by measuring the impact of such
treatments on a range of patients health outcomes.61,62
The course of patient reported outcomes such as health
status, dyspnoea and psychological status often deteriorate
significantly over time and may not strongly correlate with
changes in lung function parameters such as FEV1.
63
Change in symptoms of COPD is an important health
outcome although cannot be accurately measured. The
Breathlessness, Cough and Sputum Scale was shown to be a
reliable, valid and responsive patient-reported outcome
measure of symptom severity in patients with COPD and can
be used in clinical trials.64,65 Several instruments to measure
health status were developed, tested and validated in
patients with COPD.66–72 Heath status in COPD correlates
with severity of the disease and hypoxaemia, and the
presence of co-morbidities.73 One study which compared the
responsiveness of six instruments used to measure health
status, confirmed that the Chronic Respiratory Question-
naire (CRQ) and the Saint Georges Respiratory Questionnaire
(SGRQ) were substantially more responsive than generic
measures, and suggested particularly strong responsiveness
for the self-administered CRQ.67 ADL may be severely
ARTICLE IN PRESS
M. Cazzola et al.1052restricted in patients with COPD and their assessment
requires evaluation of the impact of disability and handicap
on daily life. The London Chest Activity of Daily Living Scale
(LCADL) was shown to be a valid tool for assessment of
patients with severe COPD.74 In a subsequent study, this
scale was also shown to be a valid outcome measure which is
reliable and responsive to change.75
Co-morbidities of COPD
COPD is a multicomponent disease. These components
affect the lungs and organs outside the lungs.76,77 The
impact of the systemic co-morbidities of COPD is substan-
tial,72,78 and although some studies have addressed the
potential mechanisms underlying these co-morbidities,
many important questions remain to be answered. Systemic
manifestations of COPD include musculoskeletal,79–81 psy-
chological,82–84 nutritional depletion,85,86 anaemia and
sexual dysfunction.87 Other pulmonary co-morbidities of
COPD include cardiovascular complications and pulmonary
hypertension,88–91 obstructive sleep apnoea92 and lung
cancer.93 Thus a comprehensive assessment of a patient
with COPD should also include assessing the systemic co-
morbidities of this disease.
Acute exacerbation of COPD
Acute exacerbation of COPD is associated with increased
morbidity and mortality.94 A variety of definitions for acute
exacerbation of COPD have been used in clinical studies.
These have been traditionally based on change in patients’
symptoms or their requirement for antibiotic therapy, oral
steroids or hospitalization.95 The importance for a standard
definition has been recently emphasized.95 From a recent
survey from 1100 subjects with symptoms compatible with
COPD,96 exacerbations generated a mean of 5.1 medical
visits/year (SD ¼ 4.6) with the mean duration of exacerba-
tion symptoms being 10.5 days. Increased coughing was the
exacerbation symptom having the strongest impact on well-
being (42%). Fifty-five percent of patients declared that
quicker symptom relief was the most desired requirement
for treatment.
The role of bacterial and viral infections as causative
factors of acute exacerbation of COPD was extensively
described in several publications over the last 50 years.97–99
In one of these classic publications, Calder et al.98 described
their experience from a 5-year study of prophylactic
antibiotic therapy in patients with chronic bronchitis. In
that study, the use of prophylactic antibiotics reduced the
number of exacerbations and the isolation of sputum
pathogens; however, it did not influence the rate of decline
in ventilatory function. This was one of the very first
longitudinal studies that utilized what later became the gold
standard outcome in assessing the natural history of the
disease; the decline in lung function.
Many patients with acute exacerbation of COPD may need
hospitalization. The presence of concurrent diseases such as
heart disease and pneumonia prolong the hospital episodes
of COPD patients78 and the use of long-term oxygen therapy
(LTOT) and of short-acting b-agonists were associated with a
late recovery from acute exacerbation of COPD.100 Factorsthat have been associated with re-admission for acute
exacerbation of COPD include: hospital admission within 1
year prior to the current exacerbation, nursing home
residency, dependency in self-care activities, right heart
strain pattern on electrocardiogram, the use of high doses of
inhaled corticosteroids (ICSs) and a serum bicarbonate level
425mmol/l.101
Management of COPD
Recent research has focussed on examining the multi-
component nature of COPD (including impairments of
metabolism and inflammation) more carefully, and deter-
mining the effects of treatment on both the systemic and
physiological aspects of COPD. In effect, the multicompo-
nent nature of COPD has provided a challenging environment
in which to develop successful treatments.
Obviously, many questions remain to be answered, but a
comprehensive approach is now considered essential to the
life-long management of COPD, and will undoubtedly reduce
the considerable socio-economic burden of COPD.102 At
present time, a combination of pharmacological and non-
pharmacological approaches seems to be effective in the
attempt to face with these problems.
Pharmacologic management
Pharmacologic management for COPD includes antibiotics,
bronchodilators, corticosteroids, and mucolytics. There are
also some other classes of drugs that are still considered of
minor importance, but worthy of clinical investigation.
Antibiotics
In 1943, May103 published an article in which he documented
that the concentrations of penicillin attainable in the
sputum of patients with chronic bronchitis or bronchiectasis
were correlated with the in vitro sensitivity to penicillin of
the infecting organisms and the clinical and bacteriological
response of the patients to treatment. This observation was
really interesting and nowadays it is still relevant. In fact,
today we consider the interrelationship between pharma-
cokinetics and pharmacodynamics extremely important in
choosing the appropriate antibiotic and the dosage regimen
for treating acute exacerbations of chronic bronchitis.104 It
must be highlighted that in May’s paper each penicillin
regime investigated gave sputum levels higher than the
sensitivity level of pneumococci, which responded satisfac-
torily to all penicillin preparations. Unfortunately, during
the ensuing decades, penicillin-resistant pneumococci has
become an area for great clinical concern worldwide
because it has been associated with treatment failure.
Up to 1980, the journal published a large amount of
papers105–128 on the use of antibiotics in the treatment or
prophylaxis of acute exacerbation of chronic bronchitis. In
effects, at that time there was a lot of interest for the
antibiotic therapy. This likely happened because the ‘‘British
hypothesis’’, which raised the concept that chronic bron-
chitis could predispose to infection, which in turn damaged
the airways and/or the alveoli, leading to progressive
airflow limitation. The continuous introduction into the
market of new anti-infective agents certainly facilitated the
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Unfortunately, most of these clinical trials of antibiotics
have compared new drugs with standard therapy in patients
with exacerbations who, in most cases, would have never
required an antibiotic if treated in real-life conditions. In
general, these studies might have been required for the
pharmaceutical companies to launch their new antibiotics,
but offered limited, if any, useful information to the
clinician. In any case, May105 wrote a review that was really
important for those times. He described in extremely
critical manner the problems related to the bacteriology
and chemotherapy of chronic bronchitis. In his conclusions,
May expressed an anticipatory view. It was his opinion that it
was possible that failure of penetration of antibiotic into
mucoid bronchial secretions in patients whose infection was
controlled by bacteriostatic therapy might explain the
failure of such therapy to give more lasting benefit. If the
organisms in the secretions were inaccessible to the
antibiotic, and there were no phagocytes present, there
was no reason why they should not remain viable indefinitely
and able to cause a fresh infection as soon as the bronchial
tissue was freed from protective antibiotic. For this reason,
he suggested that the approach to chemotherapy of chronic
bronchitis had to change from bacteriostatic, which was
common at that time, to bactericidal and, consequently,
treatment courses had to become intensive but for short
period. Interestingly, several articles108,111,117,122 have
reported that chemoprophylaxis was of no help in prevent-
ing acute exacerbations of pulmonary infection although the
attacks were milder in nature and the total number of
monthly purulent sputum specimens was less in the group
given a prophylactic antibiotic, it had no effect on time off
work in individual spells of illness and, moreover, it did not
influence the rate of deterioration in ventilatory function. It
would be interesting to know why in the following years
many researchers have spent time and money for getting the
same conclusions!
Even in the last few years, Respiratory Medicine has
published some papers devoted to the use of antibiotics in
the treatment of acute exacerbation of chronic bronchi-
tis.128–139 Also these studies, however, might have been
required for the pharmaceutical companies to launch or
support their new antibiotics (gemifloxacin, moxifloxacin,
telithromycin), but offered limited, if any, useful informa-
tion to the clinician. Nonetheless, it must be highlighted
that Banerjee et al.136 reported that treatment of COPD
with clarithromycin during the clinical stable state yields no
clinical advantages and therefore cannot be recommended
as means of eliminating sputum bacteria or preventing
infective exacerbations. This does not seem an unexpected
result that fits well with the prescriptive behaviour of
general practitioners. Miravitlles et al.137 published inter-
esting data coming from a Spanish cross-sectional observa-
tional study of ambulatory COPD patients. Treatment for
exacerbations included inhaled bronchodilators (90%), anti-
biotics (89%), ICSs (71%) and oral corticosteroids (43%); the
number of previous acute exacerbations was the main factor
associated with exacerbation treatment except for oral
corticosteroids, the use of which was associated with more
impaired pulmonary function. More intriguing is the Hasa-
ni’s138 paper, which showed that even only 7 days antibiotic
treatment slightly improved tracheobronchial clearanceand significantly decreased cough suggested a significant
role of the antibiotic treatment at least in decreasing the
risks of further and greater damage to the airway
epithelium. In any case, pneumococcal vaccination reduces
the risk of Streptococcus pneumoniae-induced COPD ex-
acerbations.139Bronchodilators
The article by Feinman and Newell140 published in 1963, was
the first paper in the journal to focus on the use of
bronchodilators for treating an obstructive airway disease. It
had the great merit of documenting that isoprenaline in a
dose of 0.4mg delivered by a self-propelled aerosol device,
gave an improvement in FEV1 on average 0.10 L better and
an improvement in VC 0.16 L better than 3min continuous
inhalation of 1% isoprenaline solution using a standard
hospital nebulizer driven by an oxygen cylinder. The authors
recognized that eventhough these differences were not
large or important clinically, the much smaller dose given by
the self-propelled aerosol device reduced the chance of side
effects and justified rejection of the more standard methods
of administration that were popular at that time.
The development of newer bronchodilators at the end of
1970s slowly moved the interest of the journal towards this
new therapeutic option.141–148 Berend et al.141 documented
that the bronchodilator response to salbutamol by inter-
mittent positive pressure ventilation (IPPV), was greater
than by metered dose inhaler (MDI) only in patients suffering
from chronic obstructive bronchitis with severe airways
obstruction and little additional benefit was gained with the
10mg dose. Jenkins and Moxham147 suggested that there is
minimal if any benefit in terms of functional status
administering regular doses above the equivalent of 200 mg
of salbutamol four times daily in COPD, although pulmonary
function (FEV1 and PEFR, but not FVC) results showed a
trend towards higher doses producing improved response
and a longer duration of action, with bronchodilation
following 2mg significantly greater than 400 mg salbutamol.
This study was broadly a forerunner of the actual tendency
to use greater than traditional dosage of long-acting b2-
agonists (LABAs), mainly formoterol, to prolong their
duration of action.149
After 1989, the number of articles that have explored the
use of bronchodilators in COPD increased in a dramatic
manner. It is almost impossible to quote all these articles,
and, consequently, only those papers that in our opinion
have been innovative, will be discussed. Hansen et al.150 and
Hansen and Andersen151 in 1994 and 1995 published two
interesting papers that documented that the replacement of
nebulizers with multidose dry powder inhalers was advanta-
geous both for the COPD patient, in terms of ease of use and
portability, and for the Local Health Service, in terms of
reducing resources spent on inhalation treatment. Cazzola
et al.152 in 1995 published one of the first articles on the use
of LABAs in the treatment of COPD. Up to 2000, the majority
of these articles have been focused on the activity of
LABAs153–157 and the possibility of combining these agents
with bronchodilators of other classes.158,159 Importantly, an
editorial published in 1999160 raised for the first time the
question of considering LABAs an alternative first choice
option for the treatment of stable COPD.
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focused on inhaled long-acting bronchodilators161–176,
although some interesting new observations on short-acting
bronchodilators have also been published,177–182 particularly
the documentation that prescription of ipratropium was
associated with increased mortality in both COPD and
asthmatic patients.180 Moreover, there have been two
interesting papers on the use of theophylline, now con-
sidered a third line agent in the therapy of COPD.183,184 In
particular, Ram et al.184 have published an evidence-based
review that has shown that theophylline continues to have a
role in the management of stable COPD, and is preferred by
patients over placebo. However, the benefits of theophylline
in stable COPD have to be weighed against the risk of
adverse effects. The documentation that tolerance to
pharmacologic bronchodilation occurs with LABAs such as
salmeterol and not with long-acting inhaled anticholinergics
such as tiotropium169 is a really intriguing finding. It must be
highlighted that the reported diminishment of bronchodi-
lator responses was relatively small, and a prospective trial
designed specifically to examine for tolerance should be
designed. Nevertheless, the concept of tolerance may need
to be considered when re-evaluating COPD patients during
chronic treatment with LABAs, considering the possibility of
using bronchodilators of different classes. Adams et al.175
have documented that once-daily tiotropium provides
significant improvement in lung function, health status,
and dyspnoea when used as maintenance therapy in
undertreated COPD patients who were not previously
receiving maintenance bronchodilator therapy. In any case,
although this potentially important problem, Jones et al.165
have observed that addition of salmeterol to COPD patients’
current therapy improved lung function, health status at the
expense of a modest increase in costs compared with usual
therapy. Considering the fact that both LABAs and tiotro-
pium are effective agents in the treatment of stable COPD,
the present trend is to combine a LABA and tiotro-
pium.170,172
The fast onset of action of formoterol161,173 has suggested
testing this bronchodilator in the treatment of acute
exacerbation of COPD. Preliminary data with LABAs162,164,167
seem to indicate that repeated doses of both formoterol and
salmeterol induce an effective dose-dependent increase in
lung function in patients suffering from COPD exacerbations,
but only formoterol induces a fast onset of action. A
suggested possible alternative to the use of higher than
recommended dose of formoterol is the combination of
formoterol and tiotropium, although the time course of the
effects of these drugs differs significantly from that in stable
COPD, with a shorter bronchodilation both for tiotropium
and formoterol.185 In any case, because of its pharmacody-
namic profile with both a rapid onset of effect, similar to
salbutamol, and a long duration of action, similar to
salmeterol, formoterol is suitable for both maintenance
and as-needed treatment in COPD.174Corticosteroids
In 1958, Ogilvie186 published an article on the treatment of
patients with severe asthma and chronic bronchitis. This
article was surely significant at that time because it had the
merit of stressing the fact that the treatment of patientswith severe asthma and chronic bronchitis was perfectly
feasible, and success might be expected in two-thirds or
more of cases. Moreover, it highlighted the importance of
calculating the cost because it was becoming increasingly
clear that there was an imperative need to reduce the cost
of certain remedies of proved and vital importance, whether
by a vast increase in the scale of production, or by other
means. Unfortunately, Ogilvie considered the treatment of
severe asthma and chronic bronchitis in the same manner
and suggested that it had to consist of the suppression, first
of all, of infective activity by antibiotic therapy, followed by
the exhibition of a suitable adrenal hormone in adequate
dosage. This initial treatment had to be followed by
maintenance therapy, but it was Olgivie’s opinion that it
could fail within 6 months if it consisted of hormone alone
(mainly, ACTH or prednisone). Consequently, successful
maintenance treatment of persistent asthma with chronic
bronchitis depended on the use both of antibiotics and
hormones on a permanent or semi-permanent basis. In any
case, this paper could be considered important still today
because it stressed that the use of ‘‘antispasmodics’’
(adrenaline hydrochloride 1 in 1000 by injection, aminophyl-
line by mouth, and what he just defined a new aerosol
solution which he was testing prior to introduction for
general use) was ineffective in a number of patients that, on
the contrary, responded very well to hormone treatment.
This is one of the first reports that patients suffering from
chronic bronchitis may present an irreversible airway
obstruction, although today this information is considered
misleading. On the contrary, the documentation that the use
of bronchodilators as a screening device for the selection of
patients for hormone treatment is valueless is still relevant.
In 1960, Ogilvie and Newell187 tested a maintenance
combined treatment with an oral corticosteroid (methyl
prednisolone) and an antibiotic (terramycin+novobiovin) in a
series of asthmatics with chronic bronchitis. They concluded
that maintenance treatment by corticosteroid had some
clinical effect on certain of these patients, which was
annulled by discontinuing it, a view supported by the
frequent clinical observation that deterioration in the
chronic asthmatic with chronic bronchitis occurs much more
readily than the reverse change. This was an intriguing
conclusion that is still relevant considering the existing
debate on the use of corticosteroids in stable COPD.188
In 1963, Hurford et al.189 explored the use of prednisolone
in chronic bronchitis. They observed that only a small
proportion (20%) of patients with chronic bronchitis and
emphysema who did not react to more conservative
treatment showed a response to a week on prednisolone
at a dose of 30mg a day and raised the suspicion that these
responders were characterized by something different
which would explain their heterogeneity. The authors also
observed that some patients, who did not respond in the
shorter period, responded to corticosteroids after longer
periods than one week. Discussing these results, they
highlighted a concept that is still a controversial issue,
although it is supported by many researchers in the field. It
was their opinion that if there are occasional cases of
chronic bronchitis in which endobronchial changes and
bronchospasm will be relieved by prednisolone, they are
probably much fewer than would appear if this drug is used
without close control with ventilatory tests. There is no
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being which will lead some patients with chronic bronchitis
to feel better able to carry on despite virtually unchanged
exercise tolerance. But this is certainly not sufficient excuse
for continuing the use of corticosteroids.
In the 1990s, some articles that related the use of
corticosteroids were published.190–194 Senderovitz et al.194
documented that in outpatients with stable COPD and no
signs of asthma or atopy, 2 weeks treatment with pre-
dnisolone seems to be of no value in choosing subsequent
long-term therapy. Stro¨m191 reported an increased mortality
in women receiving oral corticosteroid medication that was
found to be associated with an increased need of hospital
care due to longer hospital stays during the terminal stage of
the disease. This finding has an important clinical impact. In
fact, since prescriptions of the same dose of oral corticos-
teroid medication to male and female patients in COPD
could result in a greater incidence and severity of side-
effects in female patients, this practice should be debated.
Jarad et al.193 were able to document that abrupt with-
drawal of ICSs may lead to early exacerbation in stable
COPD. This is an important finding because it indicates that
clinicians should be aware of the risk of an exacerbation
developing within a few weeks of stopping this treatment
and, consequently they should never suggest to patients to
discontinue treatment with ICSs if this is not giving them
immediate benefit.
Some interesting papers194–203 have focused on the
administration of ICSs to COPD patients. They reach
contrasting results and, consequently, they confirm the
debate existing on this topic.188 Thus, it has been documen-
ted198 that early initiation of ICS treatment does not seem to
affect the progressive deterioration of lung function or other
respiratory health outcomes in subjects with early signs and
symptoms of COPD. Therefore, primary care physicians
should be careful to base maintenance treatment with ICSs
in subjects at risk for, or in an early stage of COPD on a single
spirometric evaluation performed in the first months of
treatment. However, Ayres et al.197 reported that treatment
with an ICS was associated with statistically significant
clinical benefits in patients with moderate-to-severe COPD
currently symptomatic on regular bronchodilator therapy. As
the differences in direct and total costs compared with
placebo were small and non-significant, they considered such
a type of treatment cost effective in this patient population.
Moreover, Tkacova et al.203 documented that ICS may reduce
all-cause mortality in patients with severe COPD and chronic
hypoxaemia, who require long-term domiciliary oxygen
therapy. These data suggest that ICS may indeed play an
important role in improving clinical outcomes in patients with
advanced COPD.Combination therapy
The benefit that exists when an ICS is combined with a LABA
has been discussed in several articles.204–209 Analysing
results of the TRISTAN study, Vestbo et al.205 did not find
differences between women and men with COPD in the
efficacy and safety outcomes in comparing the salmeterol/
fluticasone propionate combination versus placebo. Cazzola
et al.204 suggested that when treating patients with
formoterol, it is prudent to check their arterial blood gasesbecause this bronchodilator can worsen pretreatment
hypoxaemia. However, combined administration of formo-
terol and budesonide reduces the potential for acute effects
of formoterol on blood-gas tensions. Mapel et al.209 analysed
COPD patients from two different managed care organiza-
tions from different parts of the United States and found
that patients who used an ICS, a LABA, or an ICS plus a LABA
had better survival than patients who were only using short-
acting bronchodilators, and that this survival benefit was
preserved even after adjustment for the other clinical
factors likely to affect survival, including age, disease
severity, comorbid diseases, and smoking history. They
found that COPD patients who had a concurrent diagnosis
of asthma had better survival than those who did not, but
the benefits of ICS therapy with or without a LABA were
preserved after adjusting for asthma in the models.
Interestingly, LABA and the combination treatments are
likely to be cost-effective, at least in the United States.207Mucolytics agents
Several papers on the use of mucolytics agents in COPD were
published.210–217 In particular, Millar et al.213 were unable to
find significant differences in lung function, mucociliary
clearance curves or sputum viscosity following treatment
with N-acetylcysteine (NAC) compared to control or placebo
measurements. Even more important, Parr and Huitson214
failed to find any statistically significant difference in the
number of exacerbations between NAC or placebo groups
after a 6-month treatment, although there was a slight
trend towards improvement in the NAC group during the first
3 months of the trial. It must be highlighted that the dosage
of NAC used in these studies was really low (200 mg thrice
daily). The possibility of influencing tracheobronchial
clearance and in this way, eliciting a beneficial action in
chronic bronchitis was tested again administering NAC.
However, NAC administered by MDI did not have any
significant effect on patients’ feeling of well-being, sensa-
tion of dyspnoea, intensity of coughing, mucus production,
or expectoration or lung function,215 although another
study216 documented that orally administered NAC may
improve general well-being in patients with mild chronic
bronchitis. Considering these findings, it is not surprising
that a large randomised placebo-controlled long term (3
years) trial of the effects of NAC 600mg on a once daily basis
on the progression of disease and exacerbation rate in
patients with COPD who had frequent exacerbations (i.e., at
least two per year for 2 years) confirmed that NAC at the
dosage of 600mg daily is ineffective at prevention of
deterioration in lung function and prevention of exacerba-
tions in patients with COPD.217
These results do not support the use of this drug in COPD,
but there has been recent evidence that NAC may be
considered an antioxidant rather than a mucolytic
agent.218–222 Interestingly, van Schayck et al.223 hypothe-
sized that that anti-oxidant treatment might be relatively
more effective among those COPD patients who respond less
well to ICSs (low reversibility and heavy smoking).Alternative drugs
Considering the need for alternative drugs in the treatment
of COPD, in the last few years the journal published some
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of several different new therapeutic possibilities. These
range from the potential of prescribing montelukast in
elderly patients with moderate to severe COPD,224 to the
use of selective phosphodiesterase (PDE)4 inhibitors (cilo-
milast and roflumilast) due to their novel mechanism of
action and potent anti-inflammatory effects, coupled with a
good safety and tolerability profile,225 or to the use of a low-
dose testosterone to men with COPD in order to counteract
progressive weight loss, and loss of lean body mass that has
specifically been associated with skeletal muscle dysfunc-
tion and is frequent in COPD patients.226 Recently, Gronke et
al.227 have shown that H1 receptor antagonist cetirizine was
able to influence hypertonic saline-induced airflow obstruc-
tion in moderate-to-severe COPD. In view of the mechanisms
involved in hypertonic saline responses, it is an open
question whether stronger effects can be elicited with
higher doses and whether such effects would translate into
clinical benefits, e.g. during exacerbations. The documen-
tation that rebamipide, a gastro-protective agent used in
the treatment of gastritis and ulcerative colitis, is able to
prevent TNF-a release, neutrophil recruitment into the
airways, and MUC5AC mucin synthesis in cigarette smoke-
stimulated airway epithelium228 is another intriguing finding
because it suggests that rebamipide may be used to treat
mucus hypersecretion in cigarette smokers.
Chronic respiratory failure is the end stage of COPD.
Home oxygen therapy is the only treatment which has been
demonstrated to improve survival of COPD patients with
chronic respiratory failure, but the mortality of patients
receiving LTOT is around 50%. These poor results have
spurred the search for coadjuvant or alternative pharmaco-
logical treatments. Almitrine bismesylate is a peripheral
chemoreceptor agonist which is believed to improve
oxygenation, probably by improving the ventilation perfu-
sion mismatch. Although when used at doses of 100–200mg/
day it shows an improvement in PaO2 greater than 5mmHg,
its tolerance is poor, and the number of side-effects such as
dyspnoea and peripheral neuropathy was unacceptable. For
this reason, it has been tested at doses of 1mg/kg/day using
an intermittent schedule in a randomized double-blind
placebo-controlled study,229 but while well tolerated, at
these doses, use of almitrine is not effective in long-term
treatment of chronic hypoxaemia in COPD patients. None-
theless, in short-term treatment, the association of almi-
trine and medroxyprogesterone acetate seems to be more
efficient than either drug alone at improving arterial blood
gases in these patients.230 Moreover, it has also been
documented that four days of treatment with almitrine
improved gas exchange in a group of subjects with hepatic
cirrhosis.231Non-pharmacologic management
Non-pharmacologic management for COPD include LTOT,
nasal positive pressure ventilation (nPPV), pulmonary
rehabilitation and lung volume reduction surgery (LVRS). In
the future, it will be important to establish the precise value
of the different management strategies available for
COPD–evaluating both clinical and physiological endpoints
and using the data to more accurately define candidatepatients accordingly. The challenge will be to develop this
base of knowledge in order to shape future research and
allow clinicians to deliver tailored COPD management
programs for the growing number of patients afflicted with
this disease.232
Developing the means to measure the effects of COPD is
important, both in terms of understanding disease patho-
physiology for research purposes, and accurately assessing
the effects of treatment on the patient. Future develop-
ments will include computerizing these methodologies to
permit faster and more individual patient-centred measure-
ments.233Long-term oxygen therapy (LTOT)
Apart from smoking cessation, LTOT is the only treatment to
date which has been shown to modify the long-term decline
in lung function that is associated with COPD and, therefore,
improve survival rates in severe cases; thus its role in COPD
is well defined.232
LTOT has also been associated with a variety of benefits in
patients with severe COPD, including increased survival,
reduced secondary polycythemia, improved cardiac function
during rest and exercise, reduction in the oxygen cost of
ventilation and improved exercise tolerance. Of particular
note are the results of a longitudinal study showing that
LTOT significantly improved heath-related quality of life
(HRQoL) at 2 and 6 months, compared with a progressive
decline in HRQoL in the non-LTOT group. In the LTOT group,
67% and 68% of patients (at 2 and 6 months, respectively)
showed a clinically significant improvement in their CRQ
scores.234 Hence, there is a convincing rationale for
including LTOT in the treatment paradigm for patients with
severe COPD. Patients with PaO2o7.3 kPa (55mmHg; corre-
sponding to SaO2o88%) whose disease is stable despite
receiving otherwise comprehensive medical treatment
should receive LTOT. A patient whose PaO2 is 7.3–7.8 kPa
(55–59mmHg; SaO2 89%) should receive LTOT if they show
signs of pulmonary hypertension, cor pulmonale, erythrocy-
tosis, oedema from right heart failure or impaired mental
state. If oxygen desaturation only occurs during exercise or
sleep, then oxygen therapy should be considered specifically
under those conditions. An optimal medical regimen can be
established incorporating these guidelines, with the chief
aim of achieving an optimized ventilation:perfusion ratio
matching (V0/Q) as a means of correcting hypoxaemia.
COPD patients undergo episodes of O2 desaturation of
arterial blood during rapid eye movement sleep. Fletcher et
al.235 revealed that these desaturations occur both in non-
hypoxemic patients and in patients who are hypoxemic
during the day. Further research by Plywaczewski et al.236
showed that 47.6% of COPD patients treated with LTOTspent
430% of the night with a SaO2 of o90%, and thus required
increased oxygen flow during sleep. The administration of
oxygen at a flow-rate higher than the daytime setting
usually corrects nocturnal hypoxaemia. Conflicting evidence
surrounds the contention that patients who only desaturate
during sleep will benefit from nocturnal oxygen treatment.
But while Fletcher et al.235 found a beneficial effect of
supplemental oxygen treatment in this patient group, other
well-controlled studies have not shown that the use of
nocturnal supplemental oxygen alters mortality or clinical
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pressure.
Oxygen therapy during exercise decreases dyspnoea and
improves exercise tolerance at submaximal exertion. The
mechanical rationale underlying this observation is a
decrease in dynamic hyperinflation, and reduced ventilatory
drive. LTOT is prescribed for patients who become more
hypoxemic during exercise, or who only become hypoxemic
during exercise, with oxygen settings determined while the
patient is undergoing a typical level of exertion. Studies
evaluating the long-term benefit of oxygen treatment solely
for exercise have yet to be conducted.
In an interesting paper published in 1989,237 a total of 43
severely ill COPD patients already on 24 h, or near 24 h, per
day supplemental O2 were randomly assigned to transtra-
cheal oxygen delivery (n ¼ 22) or usual delivery of O2 by
nasal cannula or face mask (n ¼ 21). A few important
changes were found in pulmonary function over time such as
decreases of PEFR, FEF and MVV for both experimental and
control groups, and FEV1% and FEV3% in experimental
patients. At the same time, there was a significant decrease
in both haematocrit and haemoglobin, and per cent shunting
for the experimental group and a significant increase in per
cent shunting in the control group. Physical, social and
psychological assessments showed significant improvement
over time for experimental patients and declines for the
control group. Lastly, medical costs were positively af-
fected, as fewer days were spent in hospital post-study
enrolment by experimental than control groups, and post-
enrolment relative to pre-enrolment by experimental
patients.Non-invasive ventilation
Mechanical ventilation increases or substitutes for an
individual’s spontaneous respiration, as in the case of acute
respiratory or ventilatory pump failure.232 Non-invasive
ventilation, e.g. intermittent negative pressure ventilation
(INPV) or nPPV, have recently re-emerged as popular options
that avoid the risks associated with invasive ventilation.232
nPPV is thought to assist ventilation, by improving inspira-
tory flow rate and correcting hypoventilation. Other possible
mechanisms of action include resting respiratory muscles
and resetting the central respiratory drive.232
In contrast to the evidence supporting the use of nPPV to
tackle other causes of chronic respiratory failure, there is
conflicting evidence regarding the benefits of nPPV in
COPD.232 In a 12-week double-blind study of 184 patients
with severe COPD, no significant difference was observed in
6-min walk test results, cycle endurance time, severity of
dyspnoea, HRQoL, respiratory muscle strength or arterial
blood gas compared with sham treatment.238 This suggests
that inspiratory muscle rest has no benefits for patients with
severe stable COPD, although poor patient compliance may
have contributed to the results.
Regarding the administration of nPPV in patients with
severe COPD, two 3-month crossover trials of similar design
came to different conclusions.239,240 The discrepancy
between these results may be explained by the difference
between patient sets at baseline: patients with greater CO2
retention and more frequent nocturnal oxygen desaturations
may benefit more from nPPV administration.In addition to this conflicting data on physiological
endpoints there is a lack of data showing whether nPPV
treatment actually improves survival rates. Two large
multicentre trials have focused on nPPV in patients with
severe hypercapnic COPD. One trial published as an abstract
by Muir et al.241 which compared home nPPV plus LTOTwith
LTOT alone, indicated that there is no overall survival
benefit in patients receiving nPPV plus LTOT, although there
may be a slight improvement in survival for patients over 65
years of age. A 2-year Italian multicentre study also
examined the effects of nPPV plus LTOT compared with
LTOT alone (N ¼ 122).242 In this trial, nPPV plus LTOT
improved PaCO2 during breathing of the usual oxygen
inspiratory fraction. Long-term improvements were also
noted in dyspnoea and HRQoL in the nPPV plus LTOT group,
but survival was similar between treatment groups.
Currently, there is little evidence supporting the use of
mechanical ventilatory support in the routine management
of COPD.233 However, further large studies may be able to
identify subsets of patients for whom nPPV would be
beneficial.
An historical and pioneering paper published in 1958243
showed that inspiratory positive pressure breathing (IPPB)
by itself and independently has therapeutic value, particu-
larly in asthma, bronchitis and emphysema, concluding that
it probably accomplishes this result by helping to clear the
bronchial airways of obstructing secretions and exudations,
although other effects as yet unknown may be important.
The therapeutic results are erratic and the use of IPPB is
justified only by the otherwise inexorable progress to an
asphyxial death of crippling COPD. The authors suggest that
this technique may also be used as a means of temporarily
diminishing venous return in acute pulmonary oedema, and
of expanding collapsed segments of lung in respiratory
paralysis and post-operative immobilization of the lung and
they retain that the hazards of this form of treatment
are slight.LVRS for emphysema
LVRS was originally proposed as a palliative treatment for
patients with severe emphysema. The rationale for LVRS is
based on the premise that these patients have severe
hyperinflation and the goal of surgery is to remove
functionally useless emphysematous lung. Generally, this
involves the removal of 25–30% of lung tissue from both the
left and the right sides. Benefits associated with LVRS are
improved lung function (reduced lung volume and increased
FEV1) and exercise (including the distance walked in
6min).243 Although carefully selected patients benefit from
LVRS, questions remain concerning the magnitude and
duration of positive outcome.232
The National Emphysema Treatment Trial (NETT) was set
up as a multicentre, randomized, large-scale clinical trial
(N ¼ 1218) to evaluate the effects of LVRS.244 Overall results
from the NETT at 2-years post-randomization indicate that
LVRS improves exercise capacity, but does not improve
survival compared with medical therapy. Patients in the
LVRS group also reported improved health status and less
dyspnoea compared with the medical group. Subgroup
analyses showed that patients with upper-lobe predominant
emphysema and low exercise capacity had improved survival
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with245 mainly non-upper-lobe emphysema and high ex-
ercise capacity showed reduced survival. From these results,
two key outcome predictors can be identified: distribution
of emphysema and exercise capacity following pulmonary
rehabilitation. Combined with the factors placing patients
at high risk for LVRS, these predictors allow more targeted
patient selection than was previously possible.
Key questions remaining concern the role of pre-operative
pulmonary rehabilitation, the mechanisms by which LVRS
improves lung function and survival, and the impact of
different surgical techniques on LVRS outcomes.232 The
identification of long-term predictors of LVRS outcomes
would be a welcome development, while investigating
unilateral or repeated LVRS, as well as non-invasive
techniques to reduce lung volume, may prove successful in
the future.Pulmonary rehabilitation
Pulmonary rehabilitation complements pharmacotherapy
and is now considered central to the management of
symptomatic COPD.246 This form of management has
negligible effects on pulmonary function, yet commonly
provides substantial relief from dyspnoea, increased ex-
ercise tolerance and improved HRQoL.246 Pulmonary reha-
bilitation appears to work via several mechanisms, including
reducing some of the comorbidity associated with chronic
respiratory disease (such as the physical deconditioning
associated with sedentarism) and providing patients with
self-management strategies (through disease-related edu-
cation).246 Rehabilitation would also seem to reduce
subsequent health care utilization, with the valuable cost
reductions that this would imply.246
The logical concept of optimizing the pharmacologic
management of COPD patients prior to, and during,
pulmonary rehabilitation to achieve greater benefit is
becoming more widely recognized. Despite a growing body
of research evidence, further work is needed to determine
which patients will benefit most from pulmonary rehabilita-
tion, how this form of management is best prescribed, and
how to identify the most suitable practice setting, which is
dependent on the stage/phase of the disease.
Pulmonary rehabilitation is defined as an art of medical
practice in which an individually tailored, multidisciplinary
programme is formulated. It is indicated for patients
suffering from complex problems in relation to their
pulmonary disease. The goals of pulmonary rehabilitation
are: (1) to decrease the physical and psychological
manifestations of the underlying disease, i.e. reduce the
impairment due to the disease; (2) to increase physical and
mental fitness and performance, and reduce the disability;
(3) to achieve maximal social reintegration of the patient,
thus lowering the handicap.247 The ultimate goal is a
maximal functional capacity, as allowed by the pulmonary
disturbance and overall situation. The methods by which
these goals may be achieved are combined in a programme
tailored to each individual patient. It consists of: (a) an
accurate diagnosis of the disease and of the functional
limitations of the patient, (b) education about the disease,
its pathophysiology, use of medications, use of a peak flow
metre, and the avoidance of harmful or aggravating stimuli,e.g. smoking, (c) physical training to improve the physical
fitness and performance, and (d) psychosocial support. The
programme should be based on an adequate diagnosis of the
extent and character of the limitations of the individual
patient.247
Pulmonary rehabilitation is a therapeutic process, which
entails taking a holistic approach to the welfare of the
patient with chronic respiratory illness—most commonly
COPD—and is considered essential throughout the lifetime
management of patients with symptomatic chronic respira-
tory disease. It requires the coordinated action of a
multidisciplinary healthcare team in order to deliver an
individualized rehabilitation programme to best effect—in-
corporating multiple modalities such as advice on smoking
cessation, exercise training and patient self-management
education, among others. As core components of pulmonary
rehabilitation, exercise training and self-management edu-
cation have been shown to be beneficial in improving HRQoL
in patients with chronic respiratory disease. Physical
training can help to reduce the muscle de-conditioning that
occurs when the activity of patients is restricted by their
breathlessness and fatigue, and it is often associated with an
increase in patients’ HRQoL. HRQoL can also be improved by
the use of self-management education, which is designed to
provide the patient with the skills to manage the health
consequences of their disease. In doing so, patients are
better able to cope with disease symptoms, potentially
leading to reduced health care costs.247
In the last decades there was a large debate on the
effectiveness of pulmonary rehabilitation and of its differ-
ent components. For example, in a 1982 negative paper
eight patients with chronic obstructive bronchitis and
moderate disability entered a pilot study on the effects of
controlled diaphragmatic breathing. They received 3 weeks
of placebo physiotherapy (shoulder exercises) followed by
three weeks of instruction on controlled diaphragmatic
breathing. No beneficial effects were observed on exercise
performance or the perceived strain of exercise.248
Nevertheless, pulmonary rehabilitation is now supported
by a solid body of scientific evidence and is widely available
in North America and in Europe for patients with COPD. As a
paradigmatic example, the feasibility and benefits of
providing a comprehensive but cost effective pulmonary
rehabilitation programme in a UK district general hospital
has been reported.249 Two hundred and sixty-seven patients
with respiratory disability were referred for pulmonary
rehabilitation. Patients were assessed and recruited into a
7-week outpatient-based pulmonary rehabilitation pro-
gramme including elements of exercise and education
without longer-term maintenance. For all graduates, shuttle
distance increased by 58m (27%) and treadmill endurance
time increased by 15.9min (294%). The Breathing Problems
Questionnaire proved sensitive to changes in quality of life
in some domains. The Chronic Respiratory Disease Ques-
tionnaire showed significant improvements in all domains in
a sub-set of 57 patients who completed it. Longer-term
follow-up of 49 patients at a mean of 10.3 months following
pulmonary rehabilitation revealed that previous gains in
exercise performance and quality of life were maintained
with improvements in shuttle walking distance of 33m (14%
over baseline) and endurance time of 16min (280% over
baseline). The Breathing Problems Questionnaire showed no
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tionnaire showed continued improvement in a small number
of patients.References
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